Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC)
NCT06060665 · IDEAL Phase 3Completed
- Lead sponsor
- Gilead Sciences (Industry)
- Enrollment
- 96 (actual)
- Start date
- 5 Sep 2023
- Primary completion
- 6 May 2026 (actual)
- Study completion
- 6 May 2026
- Last update posted
- 4 Jun 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- Double
- Arms
- 2
Interventions
- Seladelpar 10 mg Drug
- Placebo Drug
Conditions and primary outcome
- Primary Biliary Cholangitis
Primary outcome
Percentage of Participants Response defined as Alkaline phosphatase (ALP) ≤ 1.0× Upper Limit of Normal (ULN) AND ≥ 15% Decrease in ALP at Week 52. (52 weeks); Type, Frequency, and Severity of Treatment-emergent Adverse Events. (52 weeks)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT06060665.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT06060665 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.